MiPLA

Revision as of 00:41, 16 October 2018 by >Unity (Added subjective effects)

N-Methyl-N-isopropyllysergamide (also known as methylisopropyllysergamide, Lamide and MiPLA) is a novel psychedelic substance of the lysergamide class. MiPLA is chemically similar to LSD and has a similar mechanism of action, working primarily by stimulating serotonin receptors in the brain.

MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research into LSD. It has recently been researched in greater detail by by the team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's Pharmacology notes #9 and Pharmacology notes C,

User reports describe the effects of MiPLA as similar to those of LSD with major differences. It is thought to be 1/3rd as potent as LSD itself, with an active dose reported at between 100-200 micrograms. It is often described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides.

Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.

Chemistry

MiPLA, or methylisopropyllysergamide, is a semi-synthetic alkaloid belonging to the lysergamide chemical class. MiPLA is a structural analogue of

Pharmacology

Subjective effects

MiPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

Cognitive effects
 

Combination effects

  • Alcohol - Alcohol's central depressant effects can counteract some of the anxiety and bodily tension produced by MiPLA. However, alcohol can cause dehydration, nausea and physical fatigue which can negatively impact the tone of the trip. Users are advised to pace themselves and drink a portion of their usual amount.
  • Benzodiazepines - Benzodiazepines are highly effective at reducing the intensity of MiPLA's effects through the general suppression of brain activity.
  • Cannabis - Cannabis strongly intensifies the sensory and cognitive effects of MiPLA. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
  • Dissociatives - MiPLA enhances the cognitive, visual and general hallucinatory effects of dissociatives. Dissociative-induced holes, spaces, and voids and internal hallucinations become more vivid and intense on MiPLA. These effects correspond with an increased risk of confusion, delusions, and psychosis.
  • MDMA - MiPLA and MDMA are highly synergistic and mutually enhance each other's physical, cognitive, and visual effects. The synergy between these substances is unpredictable so it is advised to start with markedly lower doses than one would take for each individually. There is some evidence that suggests that co-administration of LSD with MDMA increases the neurotoxicity of the latter,[1][2][3] and this may extend to MiPLA.

Experience reports

There are currently 1 anecdotal reports which describe the effects of this compound within our experience index.

Additional experience reports can be found here:

Literature

  • Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9

Further reading

References

  1. Armstrong, B. D., Paik, E., Chhith, S., Lelievre, V., Waschek, J. A., & Howard, S. G. (2004). Potentiation of (DL)‐3, 4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptor partial agonist d‐lysergic acid diethylamide (MiPLA), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939. Neuroscience Research Communications, 35(2), 83-95. https://doi.org/10.1002/nrc.20023
  2. Potentiation of MDMA-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists | https://indiana.pure.elsevier.com/en/publications/potentiation-of-34-methylenedioxymethamphetamine-induced-dopamine
  3. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/17572501